These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32233322)

  • 61. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How I treat hypereosinophilic syndromes.
    Klion AD
    Blood; 2015 Aug; 126(9):1069-77. PubMed ID: 25964669
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
    Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
    J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia.
    Awano N; Ryu T; Yoshimura N; Takazoe M; Kitamura S; Tanaka M
    Intern Med; 2011; 50(16):1741-5. PubMed ID: 21841337
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
    Menif S; Ben Romdhane N; Hafsia R
    Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
    Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
    Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.
    Lefèvre G; Copin MC; Staumont-Sallé D; Avenel-Audran M; Aubert H; Taieb A; Salles G; Maisonneuve H; Ghomari K; Ackerman F; Legrand F; Baruchel A; Launay D; Terriou L; Leclech C; Khouatra C; Morati-Hafsaoui C; Labalette M; Borie R; Cotton F; Gouellec NL; Morschhauser F; Trauet J; Roche-Lestienne C; Capron M; Hatron PY; Prin L; Kahn JE;
    Medicine (Baltimore); 2014 Oct; 93(17):255-266. PubMed ID: 25398061
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation.
    Curto-Barredo L; Segura S; Ishii N; Hashimoto T; Mascaró JM; Espinet B; Besses C; Pujol RM
    J Dermatol; 2019 Jun; 46(6):531-534. PubMed ID: 31021002
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Advances in diagnosis and treatment of eosinophilia.
    Sheikh J; Weller PF
    Curr Opin Hematol; 2009 Jan; 16(1):3-8. PubMed ID: 19057198
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
    Wolf D; Gastl G; Rumpold H
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
    Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
    Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Very Rare Case of Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma.
    Yamamoto T; Kamijo A; Nakazawa T; Nakajima K; Kirito K; Komatsu N; Masuyama K
    Case Rep Otolaryngol; 2018; 2018():5965029. PubMed ID: 29785315
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.
    Butterfield JH
    Leuk Res; 2009 Aug; 33(8):1127-9. PubMed ID: 19144405
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lymphocytic variant hypereosinophilic syndromes.
    Roufosse F; Cogan E; Goldman M
    Immunol Allergy Clin North Am; 2007 Aug; 27(3):389-413. PubMed ID: 17868856
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.
    Bain BJ
    Br J Haematol; 1996 Oct; 95(1):2-9. PubMed ID: 8857931
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.
    Nanagas VC; Kovalszki A
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):194-212. PubMed ID: 30003499
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clonal eosinophilic disorders and the hypereosinophilic syndrome.
    Brito-Babapulle F
    Blood Rev; 1997 Sep; 11(3):129-45. PubMed ID: 9370044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.